EMV and EEM acquired, analyzed, and graphed the data
Overall, about one in five (22%) adults who are not currently taking GLP-1 drugs (88% of the public) say they would be interested in taking a GLP-1 drug to lose weight, including just 7% who say they would be very interested. This rises to four in ten (43%) among adults who are not currently taking a GLP-1 but report being diagnosed as overweight or obese in the past five years, and about one in four (27%) among those who say they have been diagnosed with diabetes or heart disease
Some observed notable changes in their body composition and waist circumference, while others experienced gastrointestinal adverse events such as nausea, diarrhea, constipation, or headaches
While reducing the number of potential employees with access to these medications can be an effective safeguard against overrun expenses, it also limits how effective those health plans may be as talent retention and attraction tools
The changes in diet and gut microbiome associated with these medications may also indirectly impact the vaginal microbiome due to the gut-vagina axis." Beyond this, some reports have suggested that Ozempic and other GLP-1-based drugs may impact fertility, with numerous anecdotal cases of women getting pregnant on Ozempic despite using birth control
For more details, please see the Erectile Dysfunction protocol
